Actualités et vidéos - THERACLION - Anglais

Regulatory News: This press release must not be published, distributed, or disseminated, directly or indirectly, in the United Kingdom, the United States of America, Australia, Canada, or Japan. THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a robotic platform for non-invasive high-intensity focused ultrasound (HIFU) therapy, today announced the issuance of a bonds loan of up to 580,000 euros. This financing will be carried out via the issuance of warrants of...

Regulatory News: This press release must not be published, distributed, or disseminated, directly or indirectly, in the United Kingdom, the United States of America, Australia, Canada, or Japan. THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a robotic platform for non-invasive high-intensity focused ultrasound (HIFU) therapy, today announces the reserved issuance of a convertible bond loan for a maximum amount of €6 million. This financing is carried out...

Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a robotic platform for non-invasive high-intensity focused ultrasound (HIFU) therapy, announces today that its latest generation SONOVEIN® ‘SpeedPulse’ feature is being tried on patients. Major R&D breakthroughs in recent months SONOVEIN® achieved a new level of maturity in 2024, with Theraclion maintaining its focus on ongoing R&D and innovation. Key progress has recently been made on the...

Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a robotic platform for non-invasive high-intensity focused ultrasound (HIFU) therapy for the treatment of varicose veins, reports on its 2024 activities. Theraclion announced in its press release of January 6, 2025, the continuation of the strategic refocusing on the varicose veins market and confirmed its decision to no longer market its Echopulse machines intended to treat the thyroid in the near...

Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a robotic platform for non-invasive high-intensity focused ultrasound (HIFU) therapy for the treatment of varicose veins, reports on its 2024 activities. On-track progress of the pivotal FDA clinical trial Sharp increase in the number of scientific presentations and publications Over 3,000 SONOVEIN ® treatments performed to date Product maturity reached and commercialization accelerated Martin...

Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a scalable robotic platform for non-invasive ultrasound therapy, presents its review of the first half of 2023, marked by the achievement of milestones in the deployment of its strategy and the growth of its sales. Roadmap implementation In the first half of 2023, Theraclion appointed its new CEO, Martin Deterre, signed a partnership with Furui and secured the necessary funding for the next two...

Regulatory News: This document may not be distributed, directly or indirectly, in the United States, Canada, Australia or Japan. THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a scalable robotic platform for non-invasive ultrasound therapy, announces today the final signature of the strategic agreement with its long-standing partner Furui, and the completion of an issue of new shares, for a total gross amount of 8.4 million euros, with 1.3 additional million...

Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a scalable robotic platform for non-invasive ultrasound therapy, announced today the signing of a strategic agreement with its long-term partner Furui, the launch of a financing with various investors for a total amount of up to 15M€, which would allow it to finance the deployment of its strategy over 3 years, and the appointment of its new CEO, Martin Deterre. Accelerated strategy execution...

Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE) (Paris:ALTHE), an innovative company developing a scalable robotic platform for non-invasive ultrasound therapy, presents its 2022 financial results and informs on the company's short-term financing. As of the date of this press release, Theraclion is in position to meet its cash flow needs through July. Negotiations with potential strategic partners are continuing and should be concluded next month. This partnership would include a...

Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE) (Paris:ALTHE), an innovative company developing a scalable robotic platform for non-invasive ultrasound therapy, announces today that the US Food&Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application to initiate the multi-center pivotal study VEINRESET for the treatment of primary insufficiency of great saphenous veins with SONOVEIN®. Theraclion’s most significant clinical trial to date...

Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE) (Paris:ALTHE), an i nnovative company developing a scalable robotic platform for non-invasive ultrasound therapy, announces today the results of the first SONOVEIN® trial in the United States, a major milestone towards receiving FDA approval and accessing the US varicose veins market. 100% success rate in the primary end point and 95% abolition of venous reflux The definitive results show a 100% feasibility result, the primary end...

Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE) (Paris:ALTHE), an innovative company developing a scalable robotic platform for non-invasive ultrasound therapy, shares its 2022 annual report, marked by accelerated technological development and activity of the reference centers, and: 1,264 SONOVEIN® treatments performed as of December 31 st , 2022; Preliminary results similar to the standards of invasive treatments (95% reflux free after one week in the first clinical study in the...

Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE ) (Paris:ALTHE), an innovative company developing a robotic platform for non-invasive ultrasound therapy, announces that it has signed a commercial partnership with the University of Virginia (UVA), in the United States, for the use of Theraclion's latest technology in a new experimental breast cancer treatment. This pilot study, which has received FDA (Food & Drug Administration) approval, will evaluate the combined effect of high...

Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE) (Paris:ALTHE) , an innovative company developing a robotic platform for non-invasive echotherapy , shared its clinical advances at the International Symposium of Focused Ultrasound Bethesda (USA) which ended on October 27 th : the opportunity for Theraclion’s key opinion leaders to present to the scientific community their ongoing work in the management of varicose veins, thyroid nodules and breast cancer. SONOVEIN®: similar...

Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a scalable robotic platform for non-invasive ultrasound therapy to treat varicose vein disease, announced at the 2022 AVLS congress in New Orleans, Louisiana (US), on October 14 th , that the final patient enrolled in the first SONOVEIN® study in the United States has been treated. Finalized enrollment in the US study on echotherapy for varicose veins In total, 20 patients were enrolled in this...

Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE) (Paris:ALTHE), an innovative company developing a scalable robotic platform for non-invasive ultrasound therapy, is announcing a new partnership with Victor Dupouy Hospital Centre in Argenteuil (95), in the Parisian region, on echotherapy for varicose veins. Argenteuil Hospital has just invested in the SONOVEIN® robotic platform, for the non-invasive treatment of varicose veins. Based on High Intensity Focused Ultrasound (HIFU)...

Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a scalable robotic platform for non-invasive ultrasound therapy, is reaping the benefits of its focus on technology. This progress is reflected in new clinical partnerships, a growing deployment of the latest HD system among practitioners, particularly in the United States, and 4 scientific communications at the International Congress of Phlebology (#UIP2022) in Istanbul. Enhancing performance...

Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE) (Paris:ALTHE), an innovative company developing a robotic platform for non-invasive ultrasound therapy, has achieved major milestones in its development strategy in the first half of the year. R&D at the core of the new strategy Yann Duchesne, Executive Chairman of Theraclion since January 2022, is executing a new strategy. He is focusing Theraclion on improving technology performance and clinical benefits to access vein markets in...

Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE) (Paris:ALTHE), an innovative company developing a scalable robotic platform for non-invasive ultrasound therapy, announces today the presentation of echotherapy treatment results by Dr Stalnikiewicz at Swiss Vein Days 2022. The Lille-based expert achieved a 95% vein occlusion rate for all his patients since the end of his learning curve, thanks to the advanced non-invasive SONOVEIN® technology. One of the world’s first echotherapy...

Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE) (Paris:ALTHE), an innovative company developing a scalable robotic platform for noninvasive echotherapy providing consistent, data driven and evidence-based patient care , is proud to have its technology featured by Pr. David Brenin from the University of Virginia (UVA) at the annual meeting of the Society of Interventional Radiology (SIR) in Boston, on June 15 th . Pr. David Brenin, Chief of the Division of Breast and Melanoma...